SEC Info - Achieve Life Sciences, Inc. - ‘10-Q’ for 6/30/22

SEC Info℠

Home

Help

Please Sign In

Achieve Life Sciences, Inc. – ‘10-Q’ for 6/30/22 – ‘EX-101.CAL’

On: Thursday, 8/11/22, at 4:11pm ET · For: 6/30/22 · Accession #: 1564590-22-29122 · File #: 33-80623

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/11/22  Achieve Life Sciences, Inc.       10-Q        6/30/22   60:7.3M                                   ActiveDisclosure/FA

Quarterly Report — Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   2.15M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     22K 
 3: EX-32.1     Certification -- §906 - SOA'02                      HTML     20K 
 9: R1          Document and Entity Information                     HTML     75K 
10: R2          Consolidated Balance Sheets (Unaudited)             HTML    118K 
11: R3          Consolidated Balance Sheets (Parenthetical)         HTML     39K 
                (Unaudited)                                                      
12: R4          Consolidated Statements of Loss and Comprehensive   HTML     69K 
                Loss (Unaudited)                                                 
13: R5          Consolidated Statements of Cash Flows (Unaudited)   HTML     84K 
14: R6          Consolidated Statements of Stockholder's Equity     HTML     86K 
                (Unaudited)                                                      
15: R7          Nature of Business, Basis of Presentation and       HTML     28K 
                Going Concern Uncertainty                                        
16: R8          Accounting Policies                                 HTML     23K 
17: R9          Government Grant                                    HTML     23K 
18: R10         Intangibles                                         HTML     62K 
19: R11         License Agreements                                  HTML     27K 
20: R12         Fair Value Measurements                             HTML    132K 
21: R13         Convertible Debt                                    HTML     58K 
22: R14         Common Stock                                        HTML    207K 
23: R15         Commitments and Contingencies                       HTML    128K 
24: R16         Intangibles (Tables)                                HTML     62K 
25: R17         Fair Value Measurements (Tables)                    HTML    149K 
26: R18         Convertible Debt (Tables)                           HTML     70K 
27: R19         Common Stock (Tables)                               HTML    186K 
28: R20         Commitments and Contingencies (Tables)              HTML    125K 
29: R21         Nature of Business, Basis of Presentation and       HTML     43K 
                Going Concern Uncertainty - Additional Information               
                (Detail)                                                         
30: R22         Government Grant - Additional Information           HTML     31K 
                (Details)                                                        
31: R23         Intangibles - Additional Information (Detail)       HTML     29K 
32: R24         Intangibles - Components of Intangible Assets       HTML     28K 
                (Detail)                                                         
33: R25         Intangibles - Estimated Future Amortization         HTML     30K 
                Expense Related to Intangible Assets (Detail)                    
34: R26         License Agreements - Additional Information         HTML     27K 
                (Detail)                                                         
35: R27         Fair Value Measurements - Additional Information    HTML     24K 
                (Detail)                                                         
36: R28         Fair Value Measurements - Summary of Assets         HTML     30K 
                Measured at Fair Value on Recurring Basis (Detail)               
37: R29         Fair Value Measurements - Summary of Cash           HTML     27K 
                Equivalents (Detail)                                             
38: R30         Fair Value Measurements - Schedule of Aggregate     HTML     27K 
                Fair Value of Principal Amount of Convertible Debt               
                (Detail)                                                         
39: R31         Convertible Debt - Additional Information           HTML     73K 
                (Details)                                                        
40: R32         Convertible Debt - Schedule of Convertible Debt     HTML     30K 
                Balance (Details)                                                
41: R33         Common Stock - Authorized - Additional Information  HTML     27K 
                (Detail)                                                         
42: R34         Common Stock - Issued and Outstanding Shares -      HTML     57K 
                Additional Information (Detail)                                  
43: R35         Common Stock - Stock Options - Additional           HTML    100K 
                Information (Detail)                                             
44: R36         Common Stock - Summary of Stock Options Activity    HTML     34K 
                (Detail)                                                         
45: R37         Common Stock - Summary of Fair Value of Each Stock  HTML     29K 
                Award for Employees and Directors (Detail)                       
46: R38         Common Stock - Summary of Share-Based Compensation  HTML     27K 
                Expense for Stock Options, Restricted Stock and                  
                Employee Share Purchase Plan (Detail)                            
47: R39         Common Stock - Restricted Stock Unit Awards -       HTML     30K 
                Additional Information (Detail)                                  
48: R40         Common Stock - Summary of Restricted Stock Unit     HTML     37K 
                Award Activity (Detail)                                          
49: R41         Common Stock - Employee Share Purchase Plan -       HTML     24K 
                Additional Information (Detail)                                  
50: R42         Common Stock - Summary of Outstanding Warrants      HTML     52K 
                (Detail)                                                         
51: R43         Common Stock - Common Stock Warrants - Additional   HTML     31K 
                Information (Detail)                                             
52: R44         Commitments and Contingencies - Summary of          HTML     25K 
                Contractual Obligations (Detail)                                 
53: R45         Commitments and Contingencies - Additional          HTML     68K 
                Information (Detail)                                             
54: R46         Commitments and Contingencies - Summary of Future   HTML     26K 
                Minimum Annual Lease Payments (Detail)                           
55: R47         Commitments and Contingencies - Summary of Other    HTML     28K 
                Information Related to Leases (Detail)                           
58: XML         IDEA XML File -- Filing Summary                      XML    109K 
56: XML         XBRL Instance -- achv-10q_20220630_htm               XML   1.57M 
57: EXCEL       IDEA Workbook of Financial Reports                  XLSX     98K 
 5: EX-101.CAL  XBRL Calculations -- achv-20220630_cal               XML    110K 
 6: EX-101.DEF  XBRL Definitions -- achv-20220630_def                XML    496K 
 7: EX-101.LAB  XBRL Labels -- achv-20220630_lab                     XML    967K 
 8: EX-101.PRE  XBRL Presentations -- achv-20220630_pre              XML    710K 
 4: EX-101.SCH  XBRL Schema -- achv-20220630                         XSD    150K 
59: JSON        XBRL Instance as JSON Data -- MetaLinks              288±   461K 
60: ZIP         XBRL Zipped Folder -- 0001564590-22-029122-xbrl      Zip    350K

‘EX-101.CAL’ — XBRL Calculations — achv-20220630_cal

This Exhibit is an XBRL XML File.

<?xml version="1.0" encoding="windows-1252"?>

<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">

<link:roleRef xlink:type="simple" xlink:href="achv-20220630.xsd#TemplateLink" roleURI="http://achievelifesciences.com/20220630/role/TemplateLink"/>

<link:roleRef roleURI="http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited" xlink:href="achv-20220630.xsd#Role_StatementConsolidatedBalanceSheetsUnaudited" xlink:type="simple"/>

<link:calculationLink xlink:type="extended" xlink:role="http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_GrantsReceivableCurrent"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>

<link:loc xlink:href="achv-20220630.xsd#achv_OtherAssetsAndRestrictedCash" xlink:type="locator" xlink:label="achv_OtherAssetsAndRestrictedCash"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>

<link:loc xlink:href="achv-20220630.xsd#achv_AccruedLiabilitiesClinicalCurrent" xlink:type="locator" xlink:label="achv_AccruedLiabilitiesClinicalCurrent"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10060.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10070.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10080.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10090.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10120.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10130.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10140.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="achv_AccruedLiabilitiesClinicalCurrent" order="10150.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10160.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10170.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10180.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10190.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="achv_OtherAssetsAndRestrictedCash" order="10200.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10210.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="10220.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10230.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_GrantsReceivableCurrent" order="10240.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10250.00" priority="2" use="optional" weight="1.00"/>

</link:calculationLink>

<link:roleRef roleURI="http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited" xlink:href="achv-20220630.xsd#Role_StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited" xlink:type="simple"/>

<link:calculationLink xlink:type="extended" xlink:role="http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="10010.00" priority="2" use="optional" weight="-1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10020.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="10030.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="10040.00" priority="2" use="optional" weight="-1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10050.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10060.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10070.00" priority="2" use="optional" weight="1.00"/>

</link:calculationLink>

<link:roleRef roleURI="http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="achv-20220630.xsd#Role_StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>

<link:calculationLink xlink:type="extended" xlink:role="http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited">

<link:loc xlink:href="achv-20220630.xsd#achv_IncreaseDecreaseInLeaseObligations" xlink:type="locator" xlink:label="achv_IncreaseDecreaseInLeaseObligations"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>

<link:loc xlink:href="achv-20220630.xsd#achv_IncreaseDecreaseInAccruedClinicalLiabilities" xlink:type="locator" xlink:label="achv_IncreaseDecreaseInAccruedClinicalLiabilities"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>

<link:loc xlink:href="achv-20220630.xsd#achv_IncreaseDecreaseInGrantsReceivable" xlink:type="locator" xlink:label="achv_IncreaseDecreaseInGrantsReceivable"/>

<link:loc xlink:href="achv-20220630.xsd#achv_AccruedInterestOnSVBConvertibleDebt" xlink:type="locator" xlink:label="achv_AccruedInterestOnSVBConvertibleDebt"/>

<link:loc xlink:href="achv-20220630.xsd#achv_SharesIssuedAsSettlementWithTradeVendorAsNonMonetaryTransaction" xlink:type="locator" xlink:label="achv_SharesIssuedAsSettlementWithTradeVendorAsNonMonetaryTransaction"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>

<link:loc xlink:href="achv-20220630.xsd#achv_ProceedsFromAtMarketOffering" xlink:type="locator" xlink:label="achv_ProceedsFromAtMarketOffering"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10020.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="10030.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="10040.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="achv_ProceedsFromAtMarketOffering" order="10050.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="10060.00" priority="2" use="optional" weight="-1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10070.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="10080.00" priority="2" use="optional" weight="-1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10090.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="10100.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10110.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="achv_SharesIssuedAsSettlementWithTradeVendorAsNonMonetaryTransaction" order="10120.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="achv_AccruedInterestOnSVBConvertibleDebt" order="10130.00" priority="2" use="optional" weight="-1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="achv_IncreaseDecreaseInGrantsReceivable" order="10140.00" priority="2" use="optional" weight="-1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10150.00" priority="2" use="optional" weight="-1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="10160.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="10170.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="achv_IncreaseDecreaseInAccruedClinicalLiabilities" order="10180.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="10190.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="achv_IncreaseDecreaseInLeaseObligations" order="10200.00" priority="2" use="optional" weight="-1.00"/>

</link:calculationLink>

<link:roleRef roleURI="http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesComponentsOfIntangibleAssetsDetail" xlink:href="achv-20220630.xsd#Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail" xlink:type="simple"/>

<link:calculationLink xlink:type="extended" xlink:role="http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesComponentsOfIntangibleAssetsDetail">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10020.00" priority="2" use="optional" weight="-1.00"/>

</link:calculationLink>

<link:roleRef roleURI="http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail" xlink:href="achv-20220630.xsd#Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail" xlink:type="simple"/>

<link:calculationLink xlink:type="extended" xlink:role="http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail">

<link:loc xlink:href="achv-20220630.xsd#achv_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearTwo" xlink:type="locator" xlink:label="achv_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearTwo"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" order="10010.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10020.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="10030.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="achv_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearTwo" order="10040.00" priority="2" use="optional" weight="1.00"/>

</link:calculationLink>

<link:roleRef roleURI="http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleDebtBalanceDetails" xlink:href="achv-20220630.xsd#Role_DisclosureConvertibleDebtScheduleOfConvertibleDebtBalanceDetails" xlink:type="simple"/>

<link:calculationLink xlink:type="extended" xlink:role="http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleDebtBalanceDetails">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10010.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_DeferredFinanceCostsNet" order="10020.00" priority="2" use="optional" weight="-1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="10030.00" priority="2" use="optional" weight="1.00"/>

</link:calculationLink>

<link:roleRef roleURI="http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail" xlink:href="achv-20220630.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail" xlink:type="simple"/>

<link:calculationLink xlink:type="extended" xlink:role="http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFourthAndFifthYear" xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondAndThirdYear" xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInSecondAndThirdYear" order="10020.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInFourthAndFifthYear" order="10030.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear" order="10040.00" priority="2" use="optional" weight="1.00"/>

</link:calculationLink>

<link:roleRef roleURI="http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail" xlink:href="achv-20220630.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail" xlink:type="simple"/>

<link:calculationLink xlink:type="extended" xlink:role="http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10010.00" priority="2" use="optional" weight="1.00"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10020.00" priority="2" use="optional" weight="1.00"/>

</link:calculationLink>

</link:linkbase>

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/12/23  Achieve Life Sciences, Inc.       424B7                  1:173K                                   Donnelley … Solutions/FA
12/29/22  Achieve Life Sciences, Inc.       S-3                    4:276K                                   Donnelley … Solutions/FA

1 Previous Filing that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/27/22  Achieve Life Sciences, Inc.       8-K:1,2,8,9 4/26/22   14:3.8M                                   ActiveDisclosure/FA

↑Top

Filing Submission 0001564590-22-029122 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Achieve Life Sciences, Inc. – ‘10-Q’ for 6/30/22 – ‘EX-101.CAL’

On: Thursday, 8/11/22, at 4:11pm ET · For: 6/30/22 · Accession #: 1564590-22-29122 · File #: 33-80623

Quarterly Report — Form 10-QFiling Table of Contents

‘EX-101.CAL’ — XBRL Calculations — achv-20220630_cal

This Exhibit is an XBRL XML File.

2 Subsequent Filings that Reference this Filing

1 Previous Filing that this Filing References

Quarterly Report — Form 10-Q

Filing Table of Contents